Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Multiple Dose Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of PF-06282999 In Healthy Overweight Subjects And A Fixed-Sequence Study To Assess The Effect Of PF-06282999 On The Pharmacokinetics Of Midazolam In Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Midazolam (Primary) ; PF 6282999 (Primary)
- Indications Acute coronary syndromes; Anxiety disorders; Insomnia; Seizures; Sleep disorders
- Focus Pharmacokinetics
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Nov 2012 New trial record